Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer
2017-003295-31Phase 3Active
- Sponsor
- Pfizer
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Talazoparib + enzalutamide with Placebo + enzalutamide (2 arms). Primary endpoint: Radiographic progression-free survival (rPFS). Started Dec 2018; status: active.
02
Drugs
talazoparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2017-003295-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003295-31.